报价延迟最少15分钟:2026/03/10 04:42 EDT
盘前时段
|
||||
|
117.14 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
7.28/10.11
|
|
企业价值
333.03B
|
| 资产负债 |
|
每股账面净值
21.28
|
| 现金流量 |
|
现金流量率
0.06
|
| 损益表 |
|
收益
65.01B
|
|
每股收益
23.99
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographicalperspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines). |
